OS Therapies announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma

Reuters

2025/10/10

<a href="https://laohu8.com/S/OSTX">OS Therapies</a> announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma

OS Therapies Inc. announced statistically significant positive final 2-year overall survival data from its Phase 2b trial of OST-HER2, an off-the-shelf immunotherapy candidate for the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma. The results showed that 75% of OST-HER2 treated patients (27 out of 36 evaluable patients) achieved 2-year overall survival, compared with 40% in historical controls (p < 0.0001). Subgroup analysis indicated that 100% of patients who achieved 12-month Event Free Survival (EFS) reached 2-year overall survival, while 59% of those who did not achieve EFS reached 2-year overall survival. OS Therapies plans to present further data and discuss the regulatory pathway during an investor conference call scheduled for October 13, 2025. Additional prospective biomarker analyses are expected to be completed by November 2025, ahead of planned regulatory submissions in the UK, US, and EU.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 269942) on October 10, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2574112473"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2574112473\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2574112473?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-10 18:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574112473","market":"us","top_or_hot":-1,"title":"OS Therapies announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OSTX\">OS Therapies</a> announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        OS Therapies Inc. announced statistically significant positive final 2-year overall survival data from its Phase 2b trial of OST-HER2, an off-the-shelf immunotherapy candidate for the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma. The results showed that 75% of OST-HER2 treated patients (27 out of 36 evaluable patients) achieved 2-year overall survival, compared with 40% in historical controls (p &lt; 0.0001). Subgroup analysis indicated that 100% of patients who achieved 12-month Event Free Survival (EFS) reached 2-year overall survival, while 59% of those who did not achieve EFS reached 2-year overall survival. OS Therapies plans to present further data and discuss the regulatory pathway during an investor conference call scheduled for October 13, 2025. Additional prospective biomarker analyses are expected to be completed by November 2025, ahead of planned regulatory submissions in the UK, US, and EU.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 269942) on October 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OS Therapies announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOS Therapies announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-10 18:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OSTX\">OS Therapies</a> announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        OS Therapies Inc. announced statistically significant positive final 2-year overall survival data from its Phase 2b trial of OST-HER2, an off-the-shelf immunotherapy candidate for the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma. The results showed that 75% of OST-HER2 treated patients (27 out of 36 evaluable patients) achieved 2-year overall survival, compared with 40% in historical controls (p &lt; 0.0001). Subgroup analysis indicated that 100% of patients who achieved 12-month Event Free Survival (EFS) reached 2-year overall survival, while 59% of those who did not achieve EFS reached 2-year overall survival. OS Therapies plans to present further data and discuss the regulatory pathway during an investor conference call scheduled for October 13, 2025. Additional prospective biomarker analyses are expected to be completed by November 2025, ahead of planned regulatory submissions in the UK, US, and EU.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 269942) on October 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL5jKSG5:1","article_id":"2574112473","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2574112473","pubTimestamp":1760090468,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"OS Therapies Inc. announced statistically significant positive final 2-year overall survival data from its Phase 2b trial of OST-HER2, an off-the-shelf immunotherapy candidate for the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma. The results showed that 75% of OST-HER2 treated patients  achieved 2-year overall survival, compared with 40% in historical controls . Subgroup analysis indicated that 100% of patients who achieved 12-month Event Free Survival  reached 2-year overall survival, while 59% of those who did not achieve EFS reached 2-year overall survival. OS Therapies plans to present further data and discuss the regulatory pathway during an investor conference call scheduled for October 13, 2025. Additional prospective biomarker analyses are expected to be completed by November 2025, ahead of planned regulatory submissions in the UK, US, and EU.Disclaimer: This news brief was created by Public Technologies  using generative artificial intell","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","OSTX":"OS Therapies"},"translate_title":"OS Therapies宣布OSTHER2治疗转移性骨肉瘤的积极2b期试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSTX":0.9},"content_text":"OS Therapies announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma\n    \n\n        OS Therapies Inc. announced statistically significant positive final 2-year overall survival data from its Phase 2b trial of OST-HER2, an off-the-shelf immunotherapy candidate for the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma. The results showed that 75% of OST-HER2 treated patients (27 out of 36 evaluable patients) achieved 2-year overall survival, compared with 40% in historical controls (p < 0.0001). Subgroup analysis indicated that 100% of patients who achieved 12-month Event Free Survival (EFS) reached 2-year overall survival, while 59% of those who did not achieve EFS reached 2-year overall survival. OS Therapies plans to present further data and discuss the regulatory pathway during an investor conference call scheduled for October 13, 2025. Additional prospective biomarker analyses are expected to be completed by November 2025, ahead of planned regulatory submissions in the UK, US, and EU.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 269942) on October 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}